Trevena to Participate in Upcoming Conferences in June 2019

Date : 05/29/2019 @ 9:01PM
Source : GlobeNewswire Inc.
Stock : Trevena Inc (TRVN)
Quote : 0.9633  -0.0168 (-1.71%) @ 11:00PM

Trevena to Participate in Upcoming Conferences in June 2019

Trevena (NASDAQ:TRVN)
Historical Stock Chart

6 Months : From Apr 2019 to Oct 2019

Click Here for more Trevena Charts.

Trevena, Inc. (Nasdaq: TRVN), a biopharmaceutical company focused on the development and commercialization of novel medicines for patients affected by Central Nervous System conditions, today announced that Carrie Bourdow, President and Chief Executive Officer, and Mark Demitrack, SVP and Chief Medical Officer, will present at two upcoming conferences:

  • 2019 BIO International Convention, sponsored by the Biotechnology Innovation Organization, to be held at the Philadelphia Convention Center in Philadelphia, PA on Wednesday, June 5, 2019 at 3:45pm ET. Live audio webcast and archived replay of the presentation will be available on the Company’s investor relations website at https://investors.trevena.com/. Following the conclusion of the presentation, the webcast will be available for replay for 30 days.
  • JMP Securities Life Sciences Conference, sponsored by JMP Securities, to be held at The St. Regis New York in New York City on June 20, 2019 at 1:30pm ET.

For more information about the conferences, or to schedule a one-on-one meeting with the Company’s management, please contact KCSA Strategic Communications at Trevena@kcsa.com, or send an email to biopartnering@bio.org (2019 BIO International Convention), or kweisgerber@ljfevents.com (JMP Securities Life Sciences Conference). 

About TrevenaTrevena, Inc. is a biopharmaceutical company focused on the development and commercialization of novel medicines for patients affected by Central Nervous System conditions.  The Company has four novel and differentiated investigational drug candidates, including IV oliceridine, for the management of moderate to severe acute pain in hospitals, TRV250 for the acute treatment of migraine, and TRV734 for maintenance treatment of opioid use disorder.  The Company has also identified TRV045, a novel S1P receptor modulator that may offer a new, non-opioid approach to managing chronic pain.

For more information, please contact:

Investor Contact:Valter Pinto / Allison SossKCSA Strategic CommunicationsPhone: 212-896-1254 / 212-896-1267Email: IR@trevena.com  

Company Contact:Bob Yoder, SVP and Chief Business OfficerTrevena, Inc.Phone: 610-354-8840

Latest TRVN Messages

{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}}

Loading Messages....


No posts yet, be the first! No {{symbol}} Message Board. Create One! See More Posts on {{symbol}} Message Board See More Message Board Posts


Your Recent History
LSE
GKP
Gulf Keyst..
LSE
QPP
Quindell
FTSE
UKX
FTSE 100
LSE
IOF
Iofina
FX
GBPUSD
UK Sterlin..
Stocks you've viewed will appear in this box, letting you easily return to quotes you've seen previously.

Register now to create your own custom streaming stock watchlist.


NYSE, AMEX, and ASX quotes are delayed by at least 20 minutes.
All other quotes are delayed by at least 15 minutes unless otherwise stated.